Introduction
============

Hyperhomocysteinemia has been linked to cardiovascular morbidity and mortality by numerous authors ([@b11]). Whether this association is causal or not remains uncertain. Homocysteine is a sulfur-containing amino acid which can either be remethylated to methionine, or transulphurated to cysteine. In the first case, folic acid and cobalamin (vitB12) are used as coenzymes, whereas in the latter pathway pyridoxine (vitB6) is utilized ([@b7]).

Homocysteine levels below 15 μmol/L are considered normal. Hyperhomocysteinemia has been classified as follows ([@b9]): 15--30 μmol/L, moderate; 30--100 μmol/L, intermediate; higher than 100 μmol/L, severe.

This study aimed to investigate the association between hyperhomocysteinemia and the degree of carotid atherosclerosis in stroke patients.

Methods
=======

We studied 97 Greek patients (51 males, 46 females) in our stroke unit who were hospitalized as a result of ischemic stroke from March 2006 to May 2007. The mean age of the patients was 72.8 years. The patients were divided in two groups. The first included 52 stroke patients with serum levels of homocysteine below 15 μmol/L. In the second group, which included 45 patients, serum homocysteine exceeded this value. In all cases, the diagnosis of ischemic stroke was confirmed by computer tomography of the brain. Major exclusion criteria included renal failure, thyroid disease, pregnancy, hepatic failure, tumors, and drugs such as antiepileptics, fibrates, hormone replacement therapy, folate, vitB12, and vitB6 which are known to influence homocysteine levels ([@b5]).

Measurements of carotid intima-media thickness (cIMT) were performed in the far wall of both carotids at three points: a) the carotid bifurcation, b) the common carotid arteries, 1 cm proximal to the dilatation of the carotid bulb, and c) the internal carotid arteries, 1cm away from the bifurcation.

The study was approved by the Ethics Committee of our hospital.

Results
=======

The mean serum homocysteine concentration and the mean cIMT of the patients in our study were 17.4 μmol/L and 1.013 mm, respectively. [Table 1](#tbl1){ref-type="table"} sets out the main clinical and biochemical parameters for the two groups. The mean homocysteine concentration was 11.5 μmol/L in the first group and 21.5 μmol/L in the second group. The difference in cIMT between the two groups was not significant. More specifically, cIMT in the first group was 1.012 mm, and 1.015 mm in the second group.

###### 

Mean values of main clinical and biochemical parameters in the two groups

                              Group I (n = 52)   Group II (n = 47)
  --------------------------- ------------------ ---------------------------------------
  Age (years)                 72.6               72.9
  BMI (kg/m^2^)               28.4               28.1
  SBP (mmHg)                  161                166
  DBP (mmHg)                  89                 92
  Homocysteine (μmol/l)       11.5               21.5[\*](#tf1-2){ref-type="table-fn"}
  Folate (nmol/l)             21.3               16.7[\*](#tf1-2){ref-type="table-fn"}
  VitB12 (pmol/l)             401                340[\*](#tf1-2){ref-type="table-fn"}
  Total Cholesterol (mg/dl)   157                160
  LDL (mg/dl)                 114                116
  HDL (mg/dl)                 50                 47
  Triglycerides (mg/dl)       152                148
  Serum Creatinine (mg/dl)    0.91               0.94
  cIMT (mm)                   1.012              1.015

**Abbreviations:** BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; cIMT, carotid intima-media thickness.

**Notes:** statistically significant difference (p \< 0.001).

In contrast the levels of serum folate concentration in the two groups differed significantly (p \< 0.001). As expected, the level was higher in the first group (21.3 nmol/L), but significantly lower in the second group (16.7 nmol/L).

Moreover, the levels of vitB12 were also statistically different between the two groups (p \< 0.001). The mean value of vitB12 was 401 pmol/L in the first group and 340 pmol/L in the second group.

Discussion
==========

Our results indicate that serum levels of homocysteine do not correlate with cIMT in ischemic stroke patients. Therefore compared with those with low levels of homocysteine, the hyperhomocysteinemic stroke patients of our study presented with similar degree of atherosclerosis, as indicated by cIMT, which is considered to be a reliable marker of the atherosclerotic process ([@b1]).

A second conclusion was the reciprocal relationship between homocysteine and B vitamins, namely folate and vitamin B12. Both folate and vitamin B12 levels were raised in the first group, but were significantly lower in the second group. This result was not surprising, because both folate and vitamin B12 play an important role in the metabolism of homocysteine to methionine and cysteine, respectively ([@b7]). Our results confirm previous studies that reached the same conclusion ([@b2]; [@b14]; [@b13]; [@b10]).

There is still no consensus on whether homocysteine is a causative risk factor for cardiovascular events like stroke and coronary disease. Numerous epidemiological studies have correlated hyperhomocysteinemia to cardiovascular morbidity and mortality. A meta-analysis indicated that when homocysteine increases by 5 μmol/L, the relative cardiovascular risk increases by a factor of 1.6 and 1.8 in men and women, respectively ([@b3]; [@b2]). The same study estimated that 10% of the total cardiovascular risk could be attributed to hyperhomocysteinemia. In the Atherosclerosis Risk in Communities (ARIC) study, hyperhomocysteinemia was correlated with increased coronary atherosclerosis ([@b4]). The Perth Carotid Ultrasound Disease Assessment Study (CUDAS) associated homocysteine levels with carotid intima media thickness in 1111 asymptomatic patients ([@b12]). After adjustment for age, sex, and other conventional risk factors, subjects in the highest versus the lowest quartile of homocysteine had an odds ratio of 2.60 for increased IMT and 1.76 for carotid artery plaque. The authors of this study proposed that mild hyperhomocysteinemia is an independent risk factor for increased carotid artery wall thickness and plaque formation in the general population. However, other recent studies failed to confirm this result. More specifically, [@b6] found no correlation between homocysteine and IMT in the general population in Netherlands. [@b15] found a positive association between homocysteine and cIMT only in men, but not in women.

Folic acid and vitamin B12 are important factors in the homocysteine metabolism. [@b2] showed that administration of folate, vitamin B6, or vitamin B12 decreased homocysteine levels by 42%, 5%, and 15%, respectively within 6 weeks. In 1998, the United States Food and Drug Administration (FDA) required all cereal-grain products to be fortified with folic acid ([@b8]). The intention was that the typical daily ingestion of folate would increase by approximately 100 μg.

To summarize our study failed to confirm the association of hyperhomocysteinemia with cIMT in ischemic stroke patients. Large, prospective, multicentre studies are needed to more thoroughly investigate the role of homocysteine in the atherosclerotic process.
